

Liquid Embolic Agent Market Size, Share and Growth Outlook 2026: By Product Type, By Composition Type, By Application Category, By Delivery Technique, By End-User, Companies to 2034

<https://marketpublishers.com/r/LC805B7683C4EN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: LC805B7683C4EN

Abstracts

The global Liquid Embolic Agent Market size is forecast to increase from \$309.53 Million in 2026 to \$632.32 Million in 2034 at a CAGR of 9.34% between 2026 and 2034.

The Liquid Embolic Agent market report provides detailed analysis and outlook of Liquid Embolic Agent segments including By Product Type (Ethylene Vinyl Alcohol (EVOH) Copolymer-Based Agents, Cyanoacrylates (n-BCA, n-HCA), Polyvinyl Alcohol (PVA) Derivatives, Precipitating Hydrophobic Injectable Liquid Systems (PHIL)), By Composition Type (Polymer-Based Systems, Acrylic-Based / Adhesive Systems, Solvent-Based / Non-Adhesive Systems, Bioactive / Drug-Loaded Embolic Systems), By Application Category (Arteriovenous Malformations (AVMs), Intracranial Aneurysms, Dural Arteriovenous Fistulas (DAVFs), Hypervascular Tumors, Peripheral Vasculature Hemorrhage), By Delivery Technique (Microcatheter-Based Delivery, Guided Catheter Navigation, Image-Guided / Fluoroscopy-Guided Embolization), By End-User (Hospitals and Tertiary Care Medical Centers, Specialty Neurosurgical and Interventional Radiology Centers, Ambulatory Surgical Centers (ASCs)) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Liquid Embolic Agent Industry Overview

Resorbable Hydrogel Embolics Advance Peripheral Tumor Embolization

The liquid embolic agent industry is shifting toward biomaterial-based platforms that

improve vessel penetration, controlled occlusion, and post-procedure resorption in interventional radiology. Instylla, Inc. commenced commercial deployment of its Embrace™ Hydrogel Embolic System and completed its first commercial clinical procedure after receiving FDA Premarket Approval. Unlike conventional non-resorbable liquid embolics, Embrace HES uses a low-viscosity, polymer-based design consisting of two liquid precursors that combine inside the vessel to form a soft polyethylene glycol hydrogel. The system is engineered for peripheral arteries up to 5 mm and penetrates deeply into hypervascular tumor vascular beds to induce rapid occlusion. Its spontaneous hydrolysis profile, with dissolution over roughly 11 months, positions resorbable embolization as a differentiated technology pathway for tumor-directed procedures.

Peripheral Bleeding Control Expands Liquid Embolic Clinical Applications

Liquid embolic agents are gaining wider relevance beyond neurovascular procedures as manufacturers pursue peripheral vascular indications for active bleeding control. Medtronic Endovascular advanced its peripheral interventional portfolio by initiating a prospective, multi-center, non-randomized Investigational Device Exemption pivotal trial for the Onyx™ Liquid Embolic System. Although Onyx is globally recognized for neurovascular applications, the clinical expansion evaluates safety and effectiveness in the peripheral vasculature for arterial bleeding associated with trauma, pelvic fractures, and gastrointestinal ulcers. The study is designed to track up to 135 patients across 25 clinical sites in the United States, supporting broader evidence generation for liquid embolics in emergency and trauma-related vascular intervention.

Subdural Hematoma Trials Strengthen Competitive Liquid Embolic Development

Clinical development in middle meningeal artery embolization is intensifying as liquid embolic agents move into neurosurgical adjunctive care. Arsenal Medical registered the RADIANT clinical trial for its NeoCast™ Embolic System, a prospective, single-blind pivotal study evaluating middle meningeal artery embolization as an adjunct to surgical evacuation in 360 patients with symptomatic subacute or chronic subdural hematomas. The trial directly compares NeoCast against Medtronic's commercially approved Onyx liquid embolic, creating a head-to-head evidence pathway in chronic subdural hematoma treatment. This competitive structure highlights the growing importance of embolic material behavior, procedural control, clinical durability, and safety outcomes in next-generation liquid embolic agent adoption.

Liquid Embolic Agent Market Trends, Growth Drivers, Competitive Landscape, and

Future Opportunities

The global Liquid Embolic Agent market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Medtronic plc, Stryker Corporation, Boston Scientific Corporation, Johnson & Johnson MedTech (Cerenovus), Terumo Corporation, Penumbra, Inc., Balt Group, Merit Medical Systems, Inc., Instylla, Inc., B. Braun SE. The Liquid Embolic Agent market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Liquid Embolic Agent industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Liquid Embolic Agent Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Liquid Embolic Agent companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Liquid Embolic Agent markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and long-term outlook

- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Liquid Embolic Agent Market Competitive Benchmarking and Company Analysis

Leading companies in Liquid Embolic Agent industry include- Medtronic plc, Stryker Corporation, Boston Scientific Corporation, Johnson & Johnson MedTech (Cerenovus), Terumo Corporation, Penumbra, Inc., Balt Group, Merit Medical Systems, Inc., Instylla, Inc., B. Braun SE. The Liquid Embolic Agent market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Liquid Embolic Agent Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Liquid Embolic Agent market remains one of the strongest-performing segments in the country.

The US Liquid Embolic Agent Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Liquid Embolic Agent market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Liquid Embolic Agent industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Liquid Embolic Agent markets

Canada's strong Liquid Embolic Agent sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Liquid Embolic Agent market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Liquid Embolic Agent Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Liquid Embolic Agent market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Liquid Embolic Agent population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Liquid Embolic Agent industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Liquid Embolic Agent market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Liquid Embolic Agent sales through 2034

France Liquid Embolic Agent companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care

establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Liquid Embolic Agent Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Liquid Embolic Agent distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Liquid Embolic Agent Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Liquid Embolic Agent market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Liquid Embolic Agent industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Liquid Embolic Agent industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Liquid Embolic Agent Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Liquid Embolic Agent market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Liquid Embolic Agent market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Liquid Embolic Agent Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Liquid Embolic Agent Market Segmentation

By Product Type

Ethylene Vinyl Alcohol (EVOH) Copolymer-Based Agents

Cyanoacrylates (n-BCA, n-HCA)

Polyvinyl Alcohol (PVA) Derivatives

Precipitating Hydrophobic Injectable Liquid Systems (PHIL)

By Composition Type

Polymer-Based Systems

Acrylic-Based / Adhesive Systems

Solvent-Based / Non-Adhesive Systems

Bioactive / Drug-Loaded Embolic Systems

By Application Category

Arteriovenous Malformations (AVMs)

Intracranial Aneurysms

Dural Arteriovenous Fistulas (DAVFs)

Hypervascular Tumors

Peripheral Vasculature Hemorrhage

By Delivery Technique

Microcatheter-Based Delivery

Guided Catheter Navigation

Image-Guided / Fluoroscopy-Guided Embolization

By End-User

Hospitals and Tertiary Care Medical Centers

Specialty Neurosurgical and Interventional Radiology Centers

Ambulatory Surgical Centers (ASCs)

Leading Companies in Liquid Embolic Agent Industry (2026)

Medtronic plc

Stryker Corporation

Boston Scientific Corporation

Johnson & Johnson MedTech (Cerenovus)

Terumo Corporation

Penumbra, Inc.

Balt Group

Merit Medical Systems, Inc.

Instylla, Inc.

B. Braun SE

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia,
Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa,
Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Liquid Embolic Agent Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Liquid Embolic Agent Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL LIQUID EMBOLIC AGENT MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Liquid Embolic Agent Markets in 2026
- 3.2. Global Historic and Forecast Liquid Embolic Agent Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics
 - 3.4.1. Key Liquid Embolic Agent Market Driving Forces and Their Impact on Market

Outlook

- 3.4.2. Short and Long-Term Trends and Insights Shaping the Future
- 3.4.3. Potential Liquid Embolic Agent Market Opportunities for Industry Stakeholders
- 3.4.4. Potential Challenges across Liquid Embolic Agent Value Chain

CHAPTER 4- LIQUID EMBOLIC AGENT MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

- 4.1. Porter's Five Forces Analysis
 - 4.1.1. Bargaining Power of Buyers
 - 4.1.2. Bargaining Power of Suppliers
 - 4.1.3. Threat of Substitutes
 - 4.1.4. Threat of New Entrants
 - 4.1.5. Intensity of Competitive Rivalry
 - 4.1.6. Market Attractiveness Analysis by Segment
 - 4.1.7. Market Attractiveness Analysis by Region
- 4.2. Competitive Landscape
 - 4.2.1 Market Share Analysis of Leading Liquid Embolic Agent Companies
 - 4.2.2 Recent Strategic Developments
 - 4.2.3 Mergers, Acquisitions, and Partnerships
 - 4.2.4 Product Launches and Innovation Trends
 - 4.2.5 Key Success Factors
- 4.3. Value Chain Analysis
 - 4.3.1. Key Value Chain Segments
 - 4.3.2. Dominant players by value-chain stage
- 4.4. SWOT Analysis
 - 4.4.1. Key Strengths and Opportunities
 - 4.4.2. Major Weaknesses and Threats
- 4.5 Technology Roadmap
- 4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- LIQUID EMBOLIC AGENT MARKET OUTLOOK BY SEGMENTS

- 5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
 - 5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
 - 5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
- By Product Type
- Ethylene Vinyl Alcohol (EVOH) Copolymer-Based Agents
 - Cyanoacrylates (n-BCA, n-HCA)

Polyvinyl Alcohol (PVA) Derivatives
Precipitating Hydrophobic Injectable Liquid Systems (PHIL)
By Composition Type
Polymer-Based Systems
Acrylic-Based / Adhesive Systems
Solvent-Based / Non-Adhesive Systems
Bioactive / Drug-Loaded Embolic Systems
By Application Category
Arteriovenous Malformations (AVMs)
Intracranial Aneurysms
Dural Arteriovenous Fistulas (DAVFs)
Hypervascular Tumors
Peripheral Vasculature Hemorrhage
By Delivery Technique
Microcatheter-Based Delivery
Guided Catheter Navigation
Image-Guided / Fluoroscopy-Guided Embolization
By End-User
Hospitals and Tertiary Care Medical Centers
Specialty Neurosurgical and Interventional Radiology Centers
Ambulatory Surgical Centers (ASCs)

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA LIQUID EMBOLIC AGENT MARKET SIZE ANALYSIS AND OUTLOOK

7.1. North America Liquid Embolic Agent Market Overview, 2026
7.2. Leading Companies Operating in North America

7.3. Key Industry Statistics, 2026

7.4. North America Liquid Embolic Agent Market Trends and Growth Opportunities to 2034

7.5. North America Liquid Embolic Agent Market Size Outlook by Type

7.6. North America Liquid Embolic Agent Market Size Outlook by Application

7.7. North America Liquid Embolic Agent Market Size Outlook by Country

7.8. United States

7.8.1. Key Statistics

7.8.2. The US Liquid Embolic Agent Market Size Outlook, 2021- 2034

7.8.3. Key Market Drivers and Industry Developments in the US Liquid Embolic Agent Companies

7.9. Canada

7.9.1. Key Statistics

7.9.2. Canada Liquid Embolic Agent Market Size Outlook, 2021- 2034

7.9.3. Key Market Drivers and Industry Developments in Canada Liquid Embolic Agent Companies

7.10. Mexico

7.10.1. Key Statistics

7.10.2. Mexico Liquid Embolic Agent Market Size Outlook, 2021- 2034

7.10.3. Key Market Drivers and Industry Developments in Mexico Liquid Embolic Agent Companies

CHAPTER 8- EUROPE LIQUID EMBOLIC AGENT MARKET SIZE ANALYSIS AND OUTLOOK

8.1. Europe Liquid Embolic Agent Market Overview, 2026

8.2. Leading Companies Operating in Europe

8.3. Key Industry Statistics, 2026

8.4. Europe Liquid Embolic Agent Market Trends and Growth Opportunities to 2034

8.5. Europe Liquid Embolic Agent Market Size Outlook by Type

8.6. Europe Liquid Embolic Agent Market Size Outlook by Application

8.7. Europe Liquid Embolic Agent Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Liquid Embolic Agent Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Liquid Embolic Agent Companies

8.9. France

8.9.1. Key Statistics

- 8.9.2. France Liquid Embolic Agent Market Size Outlook, 2021- 2034
- 8.9.3. Key Market Drivers and Industry Developments in France Liquid Embolic Agent Companies
- 8.10. United Kingdom
 - 8.10.1. Key Statistics
 - 8.10.2. United Kingdom Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 8.10.3. Key Market Drivers and Industry Developments in the UK Liquid Embolic Agent Companies
- 8.11. Spain
 - 8.11.1. Key Statistics
 - 8.11.2. Spain Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 8.11.3. Key Market Drivers and Industry Developments in Spain Liquid Embolic Agent Companies
- 8.12. Italy
 - 8.12.1. Key Statistics
 - 8.12.2. Italy Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 8.12.3. Key Market Drivers and Industry Developments in Italy Liquid Embolic Agent Companies
- 8.13. Rest of Europe
 - 8.13.1. Key Statistics
 - 8.13.2. Rest of Europe Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Liquid Embolic Agent Companies

CHAPTER 9- ASIA PACIFIC LIQUID EMBOLIC AGENT MARKET SIZE ANALYSIS AND OUTLOOK

- 9.1. Asia Pacific Liquid Embolic Agent Market Overview, 2026
- 9.2. Leading Companies Operating in Asia Pacific
- 9.3. Key Industry Statistics, 2026
- 9.4. Asia Pacific Liquid Embolic Agent Market Trends and Growth Opportunities to 2034
- 9.5. Asia Pacific Liquid Embolic Agent Market Size Outlook by Type
- 9.6. Asia Pacific Liquid Embolic Agent Market Size Outlook by Application
- 9.7. Asia Pacific Liquid Embolic Agent Market Size Outlook by Country
- 9.8. China
 - 9.8.1. Key Statistics
 - 9.8.2. China Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 9.8.3. Key Market Drivers and Industry Developments in China Liquid Embolic Agent Companies

9.9. Japan

9.9.1. Key Statistics

9.9.2. Japan Liquid Embolic Agent Market Size Outlook, 2021- 2034

9.9.3. Key Market Drivers and Industry Developments in Japan Liquid Embolic Agent Companies

9.10. India

9.10.1. Key Statistics

9.10.2. India Liquid Embolic Agent Market Size Outlook, 2021- 2034

9.10.3. Key Market Drivers and Industry Developments in India Liquid Embolic Agent Companies

9.11. South Korea

9.11.1. Key Statistics

9.11.2. South Korea Liquid Embolic Agent Market Size Outlook, 2021- 2034

9.11.3. Key Market Drivers and Industry Developments in South Korea Liquid Embolic Agent Companies

9.12. Australia

9.12.1. Key Statistics

9.12.2. Australia Liquid Embolic Agent Market Size Outlook, 2021- 2034

9.12.3. Key Market Drivers and Industry Developments in Australia Liquid Embolic Agent Companies

9.13. Southeast Asia

9.13.1. Key Statistics

9.13.2. Southeast Asia Liquid Embolic Agent Market Size Outlook, 2021- 2034

9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Liquid Embolic Agent Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA LIQUID EMBOLIC AGENT MARKET SIZE ANALYSIS AND OUTLOOK

10.1. South and Central America Liquid Embolic Agent Market Overview, 2026

10.2. Leading Companies Operating in South and Central America

10.3. Key Industry Statistics, 2026

10.4. South and Central America Liquid Embolic Agent Market Trends and Growth Opportunities to 2034

10.5. South and Central America Liquid Embolic Agent Market Size Outlook by Type

10.6. South and Central America Liquid Embolic Agent Market Size Outlook by Application

10.7. South and Central America Liquid Embolic Agent Market Size Outlook by Country

10.8. Brazil

- 10.8.1. Key Statistics
- 10.8.2. Brazil Liquid Embolic Agent Market Size Outlook, 2021- 2034
- 10.8.3. Key Market Drivers and Industry Developments in Brazil Liquid Embolic Agent Companies
- 10.9. Argentina
 - 10.9.1. Key Statistics
 - 10.9.2. Argentina Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 10.9.3. Key Market Drivers and Industry Developments in Argentina Liquid Embolic Agent Companies
- 10.10. Rest of Latin America
 - 10.10.1. Key Statistics
 - 10.10.2. Rest of Latin America Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Liquid Embolic Agent Companies

CHAPTER 11- MIDDLE EAST AND AFRICA LIQUID EMBOLIC AGENT MARKET SIZE ANALYSIS AND OUTLOOK

- 11.1. Middle East and Africa Liquid Embolic Agent Market Overview, 2026
- 11.2. Leading Companies Operating in Middle East and Africa
- 11.3. Key Industry Statistics, 2026
- 11.4. Middle East and Africa Liquid Embolic Agent Market Trends and Growth Opportunities to 2034
- 11.5. Middle East and Africa Liquid Embolic Agent Market Size Outlook by Type
- 11.6. Middle East and Africa Liquid Embolic Agent Market Size Outlook by Application
- 11.7. Middle East and Africa Liquid Embolic Agent Market Size Outlook by Country
- 11.8. Saudi Arabia
 - 11.8.1. Key Statistics
 - 11.8.2. Saudi Arabia Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Liquid Embolic Agent Companies
- 11.9. United Arab Emirates
 - 11.9.1. Key Statistics
 - 11.9.2. The UAE Liquid Embolic Agent Market Size Outlook, 2021- 2034
 - 11.9.3. Key Market Drivers and Industry Developments in the UAE Liquid Embolic Agent Companies
- 11.10. Africa
 - 11.10.1. Key Statistics
 - 11.10.2. Africa Liquid Embolic Agent Market Size Outlook, 2021- 2034

11.10.3. Key Market Drivers and Industry Developments in Africa Liquid Embolic Agent Companies

CHAPTER 12- COMPANY PROFILES

12.1. Top Companies in Liquid Embolic Agent Industry

Medtronic plc

Stryker Corporation

Boston Scientific Corporation

Johnson & Johnson MedTech (Cerenovus)

Terumo Corporation

Penumbra, Inc.

Balt Group

Merit Medical Systems, Inc.

Instylla, Inc.

B. Braun SE

12.2. Business Description

12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Liquid Embolic Agent Market Size, Share and Growth Outlook 2026: By Product Type, By Composition Type, By Application Category, By Delivery Technique, By End-User, Companies to 2034

Product link: <https://marketpublishers.com/r/LC805B7683C4EN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LC805B7683C4EN.html>